

A- A+

Outcomes of MicroPulse Cyclophotocoagulation in Adult Glaucoma Patients

View Session	View Presentation		
Add to Schedule	Print Abstract		

Posterboard#: B0180

Abstract Number: 702 - B0180

AuthorBlock: Eric Grisham¹, Sara Hooshmand¹, Jella Angela An^{1,2}

¹University of Missouri, Columbia, Missouri, United States; ²Ophthalmology, Mason Eye Institute, Columbia, Missouri, United States;

DisclosureBlock: Eric Grisham, None; Sara Hooshmand, None; Jella Angela An, None;

Purpose

MicroPulse Transscleral Cyclophotocoagulation (mTSCPC) is used to reduce intraocular pressure (IOP) and medication burdens in glaucoma patients. However, there is no meta-analysis comparing various laser settings and the resulting potential outcomes of mTSCPC in peer-reviewed journals to date. We performed a systematic review of all published peer-reviewed literature to evaluate efficacy and safety of mTSCPC. Secondary goal was to identify the optimal setting for the IRIDEX MicroPulse P3[™] device resulting in the greatest decreases in IOP and in number of ocular hypotensive medications with the least number and severity of postoperative complications.

Methods

Two PubMed searches were performed using combinations of keywords and Medical Subject Headings evaluating safety and efficacy related to mTSCPC. Results from randomized controlled trials and review articles discussing treatment outcomes of mTSCPC procedures were included in this analysis. Reported laser settings were compared against weighted averages of preoperative and postoperative IOP and in the number of ocular hypotensive medications. Definite success was defined as an IOP reduction of 20% or more without additional medication or IOP lowering procedures, or a reduction of medication while remaining at target IOP of 18mmHg or lower.

Results

The mean number of eyes from studies analyzed at 3, 6 and 12 months was 49.3. The mean total duration of laser application was 194.44 s (SD \pm 87.83) and the mean total weighted laser power was 1992mW. Standard weighted mean differences in IOP were -1.94 (SD \pm 0.61), -2.04 (SD \pm 0.53), and -2.24 (SD \pm 0.58) for 3, 6 and 12-month follow-ups, respectively (p<0.0002). After 1 month of follow up, a significant effect was observed in changes in IOP-lowering medications. However, there was no statistically significant decrease in the number of medications 6 and 12 months post-operatively (p=0.11). Reported laser power settings did not vary statistically between studies and the effect of laser energy settings could not be measured.

Conclusions

Overall, our meta-analysis of mTSCPC literature showed that it is a safe and effective IOP-lowering procedure for many types of glaucoma patients. We identified that a number of laser settings which may be relevant to treatment outcomes are not consistently reported and studies may have excluded relevant outcomes and settings relevant to this study that were not the focus of their investigation.

Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.

Micropulse® Cyclophotocoagulation (mTSCPC) is a safe and effective laser procedure used to lower the pressure in the eyes of patients with glaucoma. Given the novelty of this technology, there is a paucity of peer-reviewed journals reporting on this procedure. We performed a systematic review of all the peer-reviewed journals reporting on safety and effectiveness of mTSCPC to better understand the outcome of mTSCPC. We determined that a number of laser settings which may be relevant to treatment outcomes were not consistently reported and studies may have excluded relevant outcomes and settings that were not the focus of their investigation. We believe that a randomized controlled trial with longer follow-up periods and more thorough evaluation and reporting of mTSCPC laser settings and outcomes is required to further evaluate the safety and prognostic factors associated with mTSCPC.

Table I. Patient Characteristics and Outcome Measures						
Continuous Variable	Weighted Average	SD				
Mean Age* (years)	64.48	0.49				
Age Range+ (years)						
Mean follow-up‡ (months)	14,20	2,41				
Mean pre-IOP (7 studies)	26.15	0.90				
Categorical Variable	Weighted Desquency	SD	Weighted Average	% of tota		
Sux (S12 eyes)						
Male	0.5475	0.32	35.04	53.20		
Formato	0.4387	0.35	28.07	47 79		
E lunicity§ (300 . yes)						
African American	0.2045	0.23	20.45	20.46		
Asian	0.0008	0.23	0.08	1.89		
Thepartic	0.1168	0.29	11.58	23.85		
White	0.5243	0.20	52.43	53.41		
Multiracial-Unspecified	0.0007	0.08	0.07	0.38		
Glascoms type\$I (622 cycs)						
PDAG	0.0314	0.83	2.14	46.95		
CACG	0.0820	0.21	6,12	4.50		
NVG	0.0109	0.68	0.66	6.20		
Everie	0.0019	0.12	0.12	1.45		
Pseudoexfoliation	0.0014	0.08	0.08	3.05		
Aphakie	0.0011	0.12	C.07	0.30		
Concentral/Javenile	0.0011	0.12	6.07	08.0		

* Bolded items represent characteristics or outcomes that had sufficient variability or sample size for comparison or consideration of success. 1 Not repared.

7 Is dt reported \$ Mean toulow-up was calculated from 251 eligible eyes; eyes not reported with

associated mandard deviations were excluded

6 Only categories shared among three or more studies were represented in Table 1 1 Aridic from POAG, no more than two studies at a time reported the same glacoenta type. Results from this study represent estimated outcomes based on consultive reporting for abacenta types.

 $\mathsf{POAG}=\mathsf{Primery}$ Opes Angle Glaucemu; CACG = Chennie Angle Closure Glaucemu: $\mathsf{NVG}=\mathsf{Nerwascular}$ Glaucemu;

TABLE 2, SUNTRARY CHINESUS, DUSING IN THE LITENSTURE				
Circul Studius	1 BC C	ndSCIC Merr total Duration	rel STC Dary	
en and Me. Geven Detroit na Me. Ged rey CO fan U. C. Bei er Me. Roem ein M. Teter wit Gevel 2. Microsofte Cyclophologica gebiete hilfeit Resid ein Refer Bry State mei Hickin men 1917	19 4 00W	\$25	61 65 10 5 m. Columna 10 m. Interació	
Angline MC Barren I, Tar Ale, Teg C. 112, Por 172, Alex PC, Marcadae Menue com e sour versen anacteratief de celopherosceptibilen i vertracery gleaserrate anderstas eau o nory cauy. Cin Esp Ophrof ref 20-3	MCC N/A	are .	3–23 (2 Cris) Substation – Trus Insectatio	
tanian 5. Measar Mill Research 17 Marcheurd Mill Frentment autoenner of mis e mine franzenie ei rectaninsi actuapulation in a transcriptiousenner (Jacob Michten 2005	M: nA	1.40	21 O Die m. constant 10 m. okawij	
1956 M.M., e.g., 1. Cirical Crisemen of Minopulser Transfere) Cysicsholocougulation in Modernic to Severe Give come . Ciri Ley, 2216	36° 1134	an.	et ak jorenes Kostan, 1 Tars alteza)	
William A., Muster MK, Kilommuya H, Grande M, et al. (Result KM, Yong K. Mitani was K. Kalani S. Ward and Y. Tanazi. "Funds of Marine Builds: "Antonial in trace as to difficult concept State on technology obtained for the set of St."	YCON	are .	1–11 (1 tris curation – Tris line tail	
Lec F. 1984 * America Spirito, Advintanti, Do Albe Controlmanos A. Un S. Lan Y. Guedens of Micropula: Lance Transis en Cyclopholographicition on Periodek Venna Adult Gia como Natiente I. Classicha, 2017	act mite	16 8.0	2139125 m condex 13 m March	
Leo AN, Franzie A, Bale J, Fregori D, A Cargada JM, Merey da cillade Leore Technical polation (NTET) A prove finite des cale selle 12 acadées at est op. 1 acres aplites frantage 1172	ACT (1)	A8-5	Talli Anna An Shangi Tana Islandi	
Velenci – «LO listo-TD, Arcoarrana «Listia , Fatient Outornes Following Microsofta Fransistani (yelophotocoegu et en listernediste term Deasts. Journal of gisuporna 2003	45 (148	IK 1/2-1	er es process Tradium, 1, 3 a cu juli escij	

Valler's de fraune, aver vez de vare ver 50% (25 x vare) o ever av el tre protetal dens to

.